Reimbursement problems rarely come from a single source in oncology infusion. Drug wastage, coding, authorization, documentation, and unit accuracy all interact. Effective Infusion Reimbursement Solutions require addressing these areas together. A single fix rarely moves total revenue in a meaningful way. This case study covers a practice facing exactly this kind of layered problem, one that only comprehensive Infusion Reimbursement Solutions could resolve.

At Infusion Billing Services, we recently completed a full engagement for a client. Their oncology practice had significant revenue loss across multiple categories. This case study explains five specific issues we identified and resolved. It also shows how comprehensive Infusion Reimbursement Solutions improved total revenue meaningfully.

Client Snapshot

Our client was a mid sized oncology infusion practice with two locations. They administered roughly 650 chemotherapy and biologic infusion visits monthly. Monthly drug spend under buy and bill exceeded 320,000 dollars. The payer mix included Medicare, commercial insurance, and Medicare Advantage plans. Commercial payers accounted for close to 44% of total claim volume, a mix that shaped the specific Infusion Reimbursement Solutions this practice needed.

We reviewed twelve months of billing and clinical data before starting this work. The overall denial rate stood at 26% before Infusion Reimbursement Solutions were applied. Several additional losses never appeared as denials at all in standard reports. This combination of denials and hidden losses shaped the scope of the Infusion Reimbursement Solutions engagement.

Issue 1: Chemotherapy Drug Wastage Never Captured for Reimbursement

Single dose chemo vials often contain more drug than one patient needs. CMS requires the JW or JZ modifier to report this difference. Several claims were missing this modifier on chemo drug charges entirely. This meant purchased drug cost was never reimbursed at all.

Problem:

• Discarded chemo drug was not reported with a wastage modifier
• Purchased drug cost exceeded what was actually billed
• Wastage tracking was not tied to inventory draw records

Fix:

• Built a wastage tracking process tied to inventory draw
• Required JW or JZ modifiers on every applicable claim
• Reconciled purchased drug against billed drug regularly

This fix recovered the single largest share of lost reimbursement identified. It became the clearest example of what Infusion Reimbursement Solutions can uncover across a full billing cycle.

Issue 2: Multi Drug Infusion Visits Coded Without Correct Hierarchy

Multi drug chemo visits follow a strict initial, sequential, and concurrent hierarchy. The highest paying code must be billed as the initial service. Several claims did not follow this hierarchy correctly during coding. This caused the practice to bill a lower paying code as primary.

Problem:

• Highest paying code was not billed as the initial service
• Hierarchy rules were not applied consistently across visits
• Multi drug visits were coded without a clear sequencing process

Fix:

• Standardized hierarchy based coding logic for chemo visits
• Reviewed drug sequence before assigning the initial code
• Trained coders on correct hierarchy rules for multi drug visits

Correcting hierarchy sequencing recovered revenue lost to silent underbilling. This became a core pillar within the broader Infusion Reimbursement Solutions built for this client, and a model other coders could follow going forward.

Issue 3: Prior Authorization Delays for High Cost Biologic Agents

High cost biologic chemo agents require thorough prior authorization. Several treatments were administered before authorization was fully confirmed. This led to full write-offs on some of the most expensive claims. These losses represented significant exposure given the drug costs involved.

Problem:

• Biologic agents were administered before authorization confirmed
• Incomplete authorization led to full claim write-offs
• High cost claims carried the largest financial exposure

Fix:

• Built a pre treatment authorization confirmation step
• Required biologic authorization confirmed before scheduling
• Reviewed authorization status before every high cost visit

Preventing early administration protected the practice’s highest value claims. This step alone justified a significant part of the Infusion Reimbursement Solutions investment.

Issue 4: Diagnosis Documentation Not Supporting Drug Specific Medical Necessity

Some claims were denied because documentation did not clearly link the drug. The connection between diagnosis, staging, and drug selection was often unclear. Payers require this link to be explicit for chemotherapy and biologic agents. Without it, claims were denied as medically unsupported.

Problem:

• Documentation did not clearly link diagnosis to drug selection
• Staging detail needed for coverage was often missing entirely
• Clinical rationale was not explicitly stated on the claim

Fix:

• Strengthened documentation linking diagnosis and drug choice
• Required explicit clinical rationale on every relevant claim
• Reviewed documentation completeness before claims were submitted

This fix reduced denials tied to the most complex, high cost treatments. Strong documentation is a foundational piece of any Infusion Reimbursement Solutions strategy.

Issue 5: ASP Based Unit Calculations Resulting in Silent Underbilling

Chemotherapy drugs are billed using average sales price based HCPCS descriptors. Units must be calculated precisely against the descriptor and vial size. Several claims miscalculated these units, resulting in silent underbilling. No denial occurred, since the claim was still technically valid.

Problem:

• Billed units did not match the ASP based HCPCS descriptor
• Vial size was not factored correctly into unit calculations
• Underbilling occurred without triggering any claim denial

Fix:

• Built a unit conversion audit for every high cost drug
• Compared billed units against descriptor and vial size
• Corrected calculations before claims left the office

This audit uncovered underbilling that standard reports never flagged. Catching this gap is a distinguishing feature of thorough Infusion Reimbursement Solutions.

How Comprehensive Infusion Reimbursement Solutions Improved Total Revenue

No single fix addressed the full scope of revenue loss on its own. Wastage, hierarchy, authorization, documentation, and unit accuracy each played a role. Fixing one area alone would have left significant revenue unrecovered. Comprehensive Infusion Reimbursement Solutions connected every stage of the process together. This combined, coordinated approach is what produced the full improvement in total revenue.

Financial Recovery Results

The table below shows the revenue impact broken down by category. These results reflect what comprehensive Infusion Reimbursement Solutions delivered overall for this oncology practice.

These results confirm that layered problems require layered solutions. No single fix could have produced this level of total recovery, which is exactly why Infusion Reimbursement Solutions must span the full revenue cycle.

Key Takeaways

These lessons show what comprehensive Infusion Reimbursement Solutions actually require.

• Chemo drug wastage must be tracked against inventory draw closely
• Multi drug visits require correct hierarchy sequencing for payment
• High cost biologics need confirmed authorization before administration
• Documentation must explicitly link diagnosis, staging, and drug choice
• ASP unit calculations should be audited even without a denial present

Conclusion

Infusion Reimbursement Solutions work best when applied across the full cycle. Wastage, coding, authorization, documentation, and unit accuracy all connect. As this case shows, addressing all five together recovered $230,000 in revenue. No single fix could have delivered this level of total improvement. This is the defining principle behind effective Infusion Reimbursement Solutions.

If your oncology practice faces layered reimbursement challenges, we can help. Infusion Billing Services builds comprehensive Infusion Reimbursement Solutions tailored to oncology infusion. Addressing the full revenue cycle protects value a single fix would miss. Our team can design Infusion Reimbursement Solutions specific to your practice’s exact gaps.

Contact Infusion Billing Services today for a full reimbursement audit. Start applying Infusion Reimbursement Solutions across your entire billing process.